Edwards Lifesciences Corporation (VIE:EWLS)

Market Cap	40.48B +5.2%
Revenue (ttm)	5.17B +11.5%
Net Income	914.30M -74.3%
EPS	1.56 -73.7%
Shares Out	n/a
PE Ratio	44.27
Forward PE	27.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	6
Open	69.64
Previous Close	70.30
Day's Range	69.64 - 70.33
52-Week Range	59.37 - 75.41
Beta	n/a
RSI	49.37
Earnings Date	Apr 30, 2026

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aor...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 1958
• Employees: 16,000
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: EWLS

Financial Performance

In 2025, Edwards Lifesciences's revenue was $6.07 billion, an increase of 11.55% compared to the previous year's $5.44 billion. Earnings were $1.07 billion, a decrease of -74.28%.

Financial numbers in USD